



Ultra-stable archaea-derived tetraether lipids that span the membrane to form monolayer-like vesicles for LNPs and liposomes

Why archaeal tetraether lipids?

Extreme stability

- Ether bonds + tetraether monolayers provide exceptional thermal, oxidative, and pH stability compared to conventional phospholipids.

Oral, parenteral, and beyond

- Demonstrated benefits in oral CBD and vancomycin delivery and in mRNA studies, with boosted bioavailability and GI (Gastrointestinal) stability.

Non-PEG stealth option

- GDGT-containing IV liposomes showed stealth behavior comparable to PEGylated formulations without PEG itself.

Platform-ready

- Applicable to small molecules, proteins, and nucleic acids; scalable manufacture under QbD principles in continuous culture.

Now available:

| Product Name | Catalog Number | Type/Role | Key Features |
|--|----------------|--|--|
| GDGT (Glycerol dialkyl glycerol tetraether) | A80588 | Native tetraether helper/stealth lipid for liposomes and LNPs | Extreme thermal/pH stability; boosts oral bioavailability and GI stability in case studies; non-PEG stealth behavior in IV liposomes |
| OHPIPD-GDGT (4-hydroxy-piperidine-Glycerol dialkyl glycerol tetraether) | A89965 | Ionizable tetraether lipid for LNP-style nucleic acid delivery | Combines GDGT backbone stability with an ionizable headgroup for complexing mRNA/saRNA/CRISPR cargos |

Use-cases

GDGT-based formulations significantly enhanced drug delivery performance, increasing oral vancomycin bioavailability by approximately ninefold without added toxicity, improving oral and parenteral mRNA bioavailability with sustained protein expression (including an ~11-fold increase for oral mRNA in rats), and providing PEG-free stealth properties that performed comparably to PEGylated liposomes in intravenous models.

Non-warranty
The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a particular purpose, non-infringement of any third-party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Unless otherwise stated, any trademarks identified herein are trademarks of the Croda group of companies.
©2026 Croda International.

Figure 1. GDGT when introduced to standard LNP (Lipid Nanoparticle) formulation:
Increases bioavailability of mRNA-based API (active pharmaceutical ingredient)




Figure 2. Unmatched Storage Stability: Lyophilized archaeosomes maintain >95% integrity after 6 months of storage, eliminating the need for ultra-cold chain logistics.




Figure 3. Superior Gastrointestinal Stability: Archaeal lipid formulations retain significantly more cargo payload after exposure to simulated gastric and intestinal fluids compared to conventional liposomes.




Figure 4. Enhanced Cellular Uptake: Archaeal lipid formulations demonstrated a 37% increase in cellular uptake compared to standard phospholipid formulations.




Figure 5. Chemical Robustness: Native GDGT lipids exhibit no degradation at Room Temperature over extended periods.

